The interim results were so strong in the endometrial trial (ridaforolimus, 3.6 months vs standard of care, 1.9 months) that Merck stopped the trial back in Oct. I'm somewhat surprised they haven't already started the P3 but this announcement will just make for more fun this Summer.
News 
Market Data 
Discover 
